Wan-Chi Hsiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wan-Chi Hsiao has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Guang-Hao Niu
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Miaoli, 35053, Taiwan
2 shared publications Li-Guo Zheng
Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804201, Taiwan
2 shared publications- Lun Kelvin Tsou
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan.
2 shared publications - Mingzi M. Zhang
Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli, 35053, Taiwan
2 shared publications - Ping-Jyun Sung
Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804201, Taiwan
2 shared publications - Zhi-Hong Wen
Department of Marine Biotechnology and Resources, National Sun Yat-Sen University, Kaohsiung, Taiwan
2 shared publications
Latest Publications
- Open Access
- 3 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Development of an orally bioavailable covalent STING inhibitor
Pharmacological inhibition of cGAS-STING-controlled innate immune pathway is an emerging therapeutic strategy for a myriad of inflammatory diseases, including autoimmune disease, ulcerative colitis, non-alcoholic fatty liver disease and aging-related neurodegeneration. Here we report GHN105 as an orally bioavailable covalent STING inhibitor. Late-stage diversification of the briarane-type diterpenoid excavatolide B allowed the installation of solubility-enhancing functional groups while enhancing its activity as a covalent STING inhibitor against multiple human STING variants, including the S154 variant responsible for a genetic autoimmune disease. Selectively engaging the membrane-proximal Cys91 residue of STING, GHN105 dose-dependently inhibited cGAS-STING signaling and type I interferon responses in cells and in vivo. Orally administered GHN105 exerted marked therapeutic efficacy and reversed key pathological features in a delayed-treatment acute colitis mouse model. Notably, we also showed that GHN105 covalently engaged STING in the colon tissues. Our study provided proof of concept that synthetic briarane analog GHN105 serves as a safe and orally active covalent STING inhibitor. With a growing number of chronic inflammatory diseases linked to aberrant STING activation, orally bioavailable STING inhibitors would benefit patients by lowering the infection risk from frequent injections while allowing long-term systemic administration.
- 3 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of an orally bioavailable covalent STING inhibitor
Pharmacological inhibition of cGAS-STING-controlled innate immune pathway is an emerging therapeutic strategy for a myriad of inflammatory diseases, including autoimmune disease, ulcerative colitis, non-alcoholic fatty liver disease and aging-related neurodegeneration. Here we report GHN105 as an orally bioavailable covalent STING inhibitor. Late-stage diversification of the briarane-type diterpenoid excavatolide B allowed the installation of solubility-enhancing functional groups while enhancing its activity as a covalent STING inhibitor against multiple human STING variants, including the S154 variant responsible for a genetic autoimmune disease. Selectively engaging the membrane-proximal Cys91 residue of STING, GHN105 dose-dependently inhibited cGAS-STING signaling and type I interferon responses in cells and in vivo. Orally administered GHN105 exerted marked therapeutic efficacy and reversed key pathological features in a delayed-treatment acute colitis mouse model. Notably, we also showed that GHN105 covalently engaged STING in the colon tissues. Our study provided proof of concept that synthetic briarane analog GHN105 serves as a safe and orally active covalent STING inhibitor. With a growing number of chronic inflammatory diseases linked to aberrant STING activation, orally bioavailable STING inhibitors would benefit patients by lowering the infection risk from frequent injections while allowing long-term systemic administration.
- Open Access
- 7 June 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Enhancing Bioactivities and Chemical Properties of A Marine Briarane-type Diterpenoid With Late-Stage Diversification
Excavatolide B (1, ExcB), a briarane-type diterpenoid isolated from Formosan gorgonian Briareum stechei, exhibits promising anti-inflammatory activity with low cytotoxicity. In this study, we report the structure-activity relationship of ExcB derivatives with late-stage modifications around the carboframe of 1. We identified a potent analog 22 with improved in vitro inhibitory activities against the inducible nitric oxide synthase gene expression, nitric oxide production, IL-6, and TNF- production in LPS-stimulated RAW264.7 macrophages. The esterification of piperidyl with proper spacer length in analog 22 also substantially increased the aqueous solubility >100-fold. More importantly, under similar dosing regimen compared to that of parent 1, 22 in its salt form showed an 80% increase in anti-inflammatory activity to alleviate carrageenan-induced paw edema in rats. Overall, these findings would greatly facilitate the further development of more potent analogs with enhanced bioactivities and improved drug-like properties of the underexplored class of briarane-type natural diterpenoids.
- 7 June 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessEnhancing Bioactivities and Chemical Properties of A Marine Briarane-type Diterpenoid With Late-Stage Diversification
Excavatolide B (1, ExcB), a briarane-type diterpenoid isolated from Formosan gorgonian Briareum stechei, exhibits promising anti-inflammatory activity with low cytotoxicity. In this study, we report the structure-activity relationship of ExcB derivatives with late-stage modifications around the carboframe of 1. We identified a potent analog 22 with improved in vitro inhibitory activities against the inducible nitric oxide synthase gene expression, nitric oxide production, IL-6, and TNF- production in LPS-stimulated RAW264.7 macrophages. The esterification of piperidyl with proper spacer length in analog 22 also substantially increased the aqueous solubility >100-fold. More importantly, under similar dosing regimen compared to that of parent 1, 22 in its salt form showed an 80% increase in anti-inflammatory activity to alleviate carrageenan-induced paw edema in rats. Overall, these findings would greatly facilitate the further development of more potent analogs with enhanced bioactivities and improved drug-like properties of the underexplored class of briarane-type natural diterpenoids.